Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Our impact
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

STAT: Global investors must support pharma solidarity and collaboration in response to COVID19

Writing in STAT, the authors call on investor colleagues to step up their engagement activities and ask all governments and pharmaceutical companies to fully embrace the principles of collaboration and solidarity in the global response to COVID-19. By Sacha Sadan, Yo Takatsuki and Damiano de Felice.

Date

28 September 2020

Direct links

Read the full opinion piece

There is a prospect of having the first supplies of at least a few effective COVID-19 medicines and vaccines by the end of 2020. Yet, many experts are questioning whether current research and manufacturing efforts can deliver these medical breakthroughs as quickly as they are being promised.

This piece written for STAT First Opinion represents a strong call for global investors to encourage all governments and pharmaceutical companies to avoid a competitive race based on medical nationalism in the world's response to COVID-19.

Companies are urged to undertake practical steps to accelerate R&D efforts and overcome potential barriers to rapid and widespread access, including sharing manufacturing capacity, agreeing to non-exclusive voluntary licensing and working with the ACT-Accelerator and the COVAX Facility. 

A strong united global response to COVID-19 can represent the first step for the investment community to better understand and manage the systemic risks of pandemic preparedness and drug-resistant infections. 

By Sacha Sadan, Director of Investment Stewardship for Legal & General Investment Management; Yo Takatsuki, Head of ESG Research and Active Ownership for AXA Investment Managers; and Damiano de Felice, Director of Strategy for the Access to Medicine Foundation.

Read the full op-ed article in STAT First Opinion. 

Suzanne Wolf

Director of Communications

Get in touch

The Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved